TG Therapeutics, Inc. Announces Second Quarter 2015 Financial Results and Business Update Investor Conference Call to be Held Today, Monday

TG Therapeutics, Inc. Announces Second Quarter 2015 Financial

Results and Business Update

Investor Conference Call to be Held Today, Monday, August

10, 2015 at 8:30am EDT

New York, NY, (August 10, 2015) - TG Therapeutics,

Inc. (NASDAQ:TGTX) today announced its financial results for the second quarter ended June 30, 2015 and recent company developments.

Michael S. Weiss, the Company's Executive Chairman and Interim

Chief Executive Officer, stated, "The second quarter was a busy and exciting time for the Company, as the data presentations

made during the quarter continue to reinforce our belief that the safety and efficacy profiles of TG-1101 and TGR-1202, alone or

in combination together in our "1303" regimen, allow for safe and efficacious multiple drug regimens, which we firmly

believe is the future of patient care in the treatment of B-cell malignancies. We remain focused on commencing additional combination

registration trials in the coming months, and aggressively recruiting into our ongoing GENUINE Phase 3 clinical trial." Mr.

Weiss continued, "From a financial perspective, with cash on hand of more than $125 million on a pro forma basis, we are

well positioned to execute on our goals and bring the Company to substantial value creating milestones."

Recent Developments and Highlights

Reaffirming 2015 Milestones

Financial Results for the Second Quarter 2015

At June 30, 2015 the Company had cash, cash equivalents, investment

securities, and interest receivable of $110.6 million, which includes approximately $51.2

million of net proceeds from the utilization of the Company's at-the-market ("ATM")

sales facility during the year (approximately $42 million of which was previously disclosed in connection with our last quarterly

update), as compared to December 31, 2014 when we had $78.9 million.

Pro-forma cash, cash equivalents, investment securities, and

interest receivable as of June 30, 2015 are approximately $126.4 million, including $15.8 million of net proceeds from the utilization

of the ATM sales facility during the third quarter of 2015.

Our consolidated net loss for the second quarter ended June

30, 2015, excluding non-cash items, was approximately $10.9 million, which included approximately $4.8 million of manufacturing

and CMC expenses in preparation for Phase 3 clinical trials and commercialization. The consolidated net loss for the second quarter

ended June 30, 2015, inclusive of non-cash items, was $17.1 million, or $0.38 per diluted share, compared to a consolidated net

loss of $12.0 during the comparable quarter in 2014, representing an increase in consolidated net loss of $5.1 million. The increase

in consolidated net loss during the second quarter ended June 30, 2015 was primarily the result of other research and development

expenses for TG-1101 and TGR-1202 increasing approximately $5.8 million and $1.3 million, respectively, over the comparable period

in 2014. The increase in other research and development expenses related to TG-1101 was primarily the result of increased manufacturing

and clinical trial expenses related to ongoing and planned future Phase 3 registration programs. These increases were partially

offset by the $1.2 million of non-cash stock expense recorded in conjunction with the license to the IRAK4 inhibitors program during

the quarter ended June 30, 2014 and a decrease of $1.5 million in non-cash compensation expense related to equity incentive grants

over the comparable period in 2014.

Our consolidated net loss for the six months ended June 30,

2015, excluding non-cash items, was approximately $20.1 million, which included approximately $9.1 million of manufacturing and

CMC expenses in preparation for Phase 3 clinical trials and commercialization. The consolidated net loss for the six months ended

June 30, 2015, inclusive of non-cash items, was $31.7 million, or $0.73 per diluted share, compared to a consolidated net loss

of $19.5 million during the comparable period in 2014, representing an increase in consolidated net loss of $12.2 million. The

increase in consolidated net loss during the six months ended June 30, 2015 was primarily the result of other research and development

expenses for TG-1101 and TGR-1202 increasing approximately $9.8 million and $2.5 million, respectively, over the comparable period

in 2014. The increase in other research and development expenses related to TG-1101 was primarily the result of increased manufacturing

and clinical trial expenses related to ongoing and planned future Phase 3 registration programs.

Conference Call Information

The Company will host an investor conference call today, August

10, 2015, at 8:30am EDT, to discuss the Company's second quarter 2015 financial results and provide a business outlook for

the remainder of 2015.

In order to participate in the conference call, please call

1-877-407-8029 (U.S.), 1-201-689-8029 (outside the U.S.), Conference Title: TG Therapeutics Second Quarter 2015 Earnings Call.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of

the Company's website at www.tgtherapeutics.com. An audio recording of the conference call will also be available for replay at

www.tgtherapeutics.com, for a period of 30 days after the call.

ABOUT TG THERAPEUTICS, INC.

TG Therapeutics is a biopharmaceutical company focused on the

acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently,

the company is developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a novel, glycoengineered

monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics

is also developing TGR-1202, an orally available PI3K delta inhibitor. The delta isoform of PI3K is strongly expressed in cells

of hematopoietic origin and is believed to be important in the proliferation and survival of B-lymphocytes. Both TG-1101 and TGR-1202

are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs to develop IRAK4

inhibitors, and anti-PD-L1 and anti-GITR antibodies. TG Therapeutics is headquartered in New York City.

Cautionary Statement

Some of the statements included in this press release, particularly

those with respect to anticipating future clinical trials, the timing of commencing or completing such trials and business prospects

for TG-1101, TGR-1202, the IRAK4 inhibitor program, and the anti-PD-L1 and anti-GITR antibodies may be forward-looking statements

that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking

statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results

to differ materially are the following: our ability to successfully and cost-effectively complete pre-clinical and clinical trials

for TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1 and anti-GITR antibodies; the risk that early pre-clinical

and clinical results that supported our decision to move forward with TG-1101, TGR-1202, the IRAK4 inhibitor program and the anti-PD-L1

and anti-GITR antibodies will not be reproduced in additional patients or in future studies; the risk that trends observed which

underlie certain assumptions of future performance of TGR-1202 will not continue, the risk that TGR-1202 will not produce satisfactory

safety and efficacy results to warrant further development following the completion of the current Phase 1 study; the risk that

the data (both safety and efficacy) from future clinical trials will not coincide with the data produced from prior pre-clinical

and clinical trials; the risk that trials will take longer to enroll than expected; our ability to achieve the milestones we project

over the next year; our ability to manage our cash in line with our projections, and other risk factors identified from time to

time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release

speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect

events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com.

The information found on our website is not incorporated by reference into this press release and is included for reference purposes

Director- Investor Relations

TG Therapeutics, Inc.

Telephone: 212.554.4351

Email: ir@tgtxinc.com

Selected Consolidated Financial Data

of Operations Information (Unaudited):

Condensed Balance Sheet Information:

* Condensed from audited financial statements.